Acute Pain Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Pfizer, Pharmbio Korea Co., Ltd., Xgene Pharma, Mylan Specialty, Allay Therapeutics

Posted on
by

Acute Pain Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Pfizer, Pharmbio Korea Co., Ltd., Xgene Pharma, Mylan Specialty, Allay Therapeutics
Within the 7MM countries the Acute Pain market size is anticipated to grow rapidly with a significant CAGR during the study period (2020-2034).

The Acute Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics.  

 

The Acute Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Pain Market Insights

 

Some of the key facts of the Acute Pain Market Report: 

  • The Acute Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034) 

  • In 2021, the overall market size for acute pain in the United States was approximately USD 3 billion, and it is anticipated to increase throughout the research duration spanning from 2020 to 2034.

  • In January 2024, Vertex Pharmaceuticals reported encouraging outcomes from its Phase III initiative evaluating VX-548, a selective NaV1.8 inhibitor, for managing moderate-to-severe acute pain. This Phase III program encompassed two pivotal trials conducted post abdominoplasty and bunionectomy surgeries, respectively, both designed as randomized, double-blind, placebo-controlled studies. Additionally, a safety and efficacy investigation, devoid of a placebo group, included patients with diverse surgical and non-surgical pain conditions.

  • In 2023, there were approximately 42 million instances of postoperative pain cases in the United States, with trauma pain and acute medical illness following closely behind. These numbers are projected to rise by 2034.

  • DelveInsight’s projections indicate that in 2023, the United States saw approximately 36 million mild cases, around 45 million moderate cases, and about 15 million severe cases. These numbers are anticipated to climb throughout the study period from 2020 to 2034.

  • In 2023, close to 80 million instances of treated acute pain were identified in the United States. Projections suggest that these numbers will rise during the forecast period from 2024 to 2034.

  • Key Acute Pain Companies: Pharmbio Korea Co., Ltd., Xgene Pharmaceutical, Mylan Specialty, Allay Therapeutics, Inc., Johnson & Johnson, RDC Clinical Pty Ltd, Halia Therapeutics, Inc., Cessatech A/S, Primus Pharmaceuticals, Olatec Therapeutics LLC, Jiangsu HengRui Medicine, Pfizer, and others

  • Key Acute Pain Therapies: PBK_L1704 0.35mg, XG005 tablet, MR-107A-02, ATX-101, Acetaminophen/Naproxen Sodium Fixed Combination, Levagen+, HT-6184, CT001, Metaxalone 640 mg Oral Tablet, Dapansutrile, Bupivacaine Liposome Injection, Zavegepant, and others 

  • The Acute Pain epidemiology based on gender analyzed that, it can be concluded that there is no significant difference in occurrence of acute pain among male and female population

 

Acute Pain Overview

Acute pain is a type of pain that typically begins suddenly and is usually short-lived. It serves as a protective mechanism, alerting the body to potential injury or tissue damage. Acute pain can result from various causes, such as injury, surgery, or medical conditions like infections or inflammation. It is often described as sharp, intense, and localized to a specific area of the body.

 

Get a Free sample for the Acute Pain Market Report:

https://www.delveinsight.com/report-store/acute-pain-market

 

Acute Pain Market  

The dynamics of the Acute Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 

“Of the emerging therapies, one of the most anticipated product to get launched is CL-108. Apart from this, several other molecules are in mid to late stage.”

 

Acute Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Download the report to understand which factors are driving Acute Pain epidemiology trends @ Acute Pain Epidemiological Insights

 

Acute Pain Epidemiology Segmentation:

The Acute Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Acute Pain

  • Prevalent Cases of Acute Pain by severity

  • Gender-specific Prevalence of Acute Pain

  • Diagnosed Cases of Episodic and Chronic Acute Pain

 

Acute Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Pain market or expected to get launched during the study period. The analysis covers Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Acute Pain treatment, visit @ Acute Pain Medications

 

Acute Pain Therapies and Key Companies

  • PBK_L1704 0.35mg: Pharmbio Korea Co., Ltd.

  • XG005 tablet: Xgene Pharmaceutical

  • MR-107A-02: Mylan Specialty, L

  • ATX-101: Allay Therapeutics, Inc.

  • Acetaminophen/Naproxen Sodium Fixed Combination: Johnson & Johnson

  • Levagen+: RDC Clinical Pty Ltd

  • HT-6184: Halia Therapeutics, Inc.

  • CT001: Cessatech A/S

  • Metaxalone 640 mg Oral Tablet: Primus Pharmaceuticals

  • Dapansutrile: Olatec Therapeutics LLC

  • Bupivacaine Liposome Injection: Jiangsu HengRui Medicine

  • Zavegepant: Pfizer

 

Acute Pain Strengths

  • Growing research and development is increasing the demand for better diagnosis and treatment options for acute pain. 

  • Recently, drugs with novel mechanisms of action and combinations are being investigated to overcome the challenges of this entity. 

  • Rising awareness about multimodal analgesia among clinicians and patient.

 

Acute Pain Opportunities

  • The market needs new therapy with superior efficacy as strong as opioids, but fewer side effect and drug dependency. 

  • Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.

 

Scope of the Acute Pain Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Acute Pain Companies: Pharmbio Korea Co., Ltd., Xgene Pharmaceutical, Mylan Specialty, Allay Therapeutics, Inc., Johnson & Johnson, RDC Clinical Pty Ltd, Halia Therapeutics, Inc., Cessatech A/S, Primus Pharmaceuticals, Olatec Therapeutics LLC, Jiangsu HengRui Medicine, Pfizer, and others

  • Key Acute Pain Therapies: PBK_L1704 0.35mg, XG005 tablet, MR-107A-02, ATX-101, Acetaminophen/Naproxen Sodium Fixed Combination, Levagen+, HT-6184, CT001, Metaxalone 640 mg Oral Tablet, Dapansutrile, Bupivacaine Liposome Injection, Zavegepant, and others

  • Acute Pain Therapeutic Assessment: Acute Pain current marketed and Acute Pain emerging therapies

  • Acute Pain Market Dynamics: Acute Pain market drivers and Acute Pain market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Acute Pain Unmet Needs, KOL’s views, Analyst’s views, Acute Pain Market Access and Reimbursement 

 

Discover more about therapies set to grab major Acute Pain market share @ Acute Pain market forecast

 

Table of Contents 

1. Acute Pain Market Report Introduction

2. Executive Summary for Acute Pain

3. SWOT analysis of Acute Pain

4. Acute Pain Patient Share (%) Overview at a Glance

5. Acute Pain Market Overview at a Glance

6. Acute Pain Disease Background and Overview

7. Acute Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Pain 

9. Acute Pain Current Treatment and Medical Practices

10. Acute Pain Unmet Needs

11. Acute Pain Emerging Therapies

12. Acute Pain Market Outlook

13. Country-Wise Acute Pain Market Analysis (2020–2034)

14. Acute Pain Market Access and Reimbursement of Therapies

15. Acute Pain Market Drivers

16. Acute Pain Market Barriers

17.  Acute Pain Appendix

18. Acute Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/